āĻšā§āĻŽALCLS âĸ EPA
add
Cellectis SA
āĻāĻžāϞ āĻļā§āώ āϝ⧠āĻĻāĻžāĻŽā§ āĻāĻŋāϞ
⧍.ā§Šā§§âŦ
āϏāĻžāϰāĻž āĻĻāĻŋāύā§āϰ āĻā§āϰā§āĻĄāĻŋāĻā§ā§ āϏā§āĻāĻā§āϰ āĻĻāĻžāĻŽā§āϰ āĻāĻ āĻž āύāĻžāĻŽāĻžāϰ āϰā§āĻā§āĻ
⧍.ā§Šā§ĒâŦ - ⧍.ā§Ē⧝âŦ
āϏāĻžāϰāĻž āĻŦāĻāϰā§āϰ āϰā§āĻā§āĻ
ā§§.ā§Ļā§§âŦ - ā§Š.⧍ā§ĻâŦ
āĻŽāĻžāϰā§āĻā§āĻ āĻā§āϝāĻžāĻĒ
ā§§ā§.ā§Šā§¯Â āĻā§ EUR
āĻāĻĄāĻŧ āĻāϞāĻŋāĻāĻŽ
ā§Š.ā§¯ā§ŠÂ āϞāĻž
P/E āĻ
āύā§āĻĒāĻžāϤ
-
āϞāĻā§āϝāĻžāĻāĻļ āĻĒā§āϰāĻĻāĻžāύ
-
āĻĒā§āϰāĻžāĻāĻŽāĻžāϰāĻŋ āĻāĻā§āϏāĻā§āĻā§āĻ
EPA
āĻāĻŦāϰ⧠āϰā§ā§āĻā§
āĻĢāĻžāĻāύāĻžāύā§āϏāĻŋā§āĻžāϞ āĻĒāĻžāϰāĻĢāϰā§āĻŽā§āϝāĻžāύā§āϏ
āĻā§ā§āϰ āϏā§āĻā§āĻāĻŽā§āύā§āĻ
āĻāĻĒāĻžāϰā§āĻāύ
āύā§āĻ āĻāύāĻāĻžāĻŽ
(USD) | āĻŽāĻžāϰā§āĻ ā§¨ā§Ļ⧍ā§Ģinfo | Y/Y āĻĒāϰāĻŋāĻŦāϰā§āϤāύ |
---|---|---|
āĻāĻĒāĻžāϰā§āĻāύ | ā§§.⧍ā§Ļ āĻā§ | ā§Žā§Ģ.ā§§ā§Ļ% |
āĻŦā§āϝāĻŦāϏāĻž āĻāĻžāϞāĻžāύā§āϰ āĻāϰāĻ | ⧍.ā§Ŧā§¨Â āĻā§ | -ā§Ē.ā§Šā§Š% |
āύā§āĻ āĻāύāĻāĻžāĻŽ | -ā§§.ā§Žā§§Â āĻā§ | -ā§Ē⧍⧧.⧍ā§Ģ% |
āύā§āĻ āĻĒā§āϰāĻĢāĻŋāĻ āĻŽāĻžāϰā§āĻāĻŋāύ | -ā§§ā§Ģā§Ļ.ā§ā§§ | -⧍ā§ā§Š.ā§Ģā§Ģ% |
āĻļā§ā§āĻžāϰ āĻĒā§āϰāϤāĻŋ āĻāĻĒāĻžāϰā§āĻāύ | -ā§Ļ.ā§§ā§ | -⧍⧧.ā§Ēā§Š% |
EBITDA | -ā§§.ā§§ā§§Â āĻā§ | ā§Šā§¯.ā§Šā§Ļ% |
āĻĒā§āϰāϝā§āĻā§āϝ āĻā§āϝāĻžāĻā§āϏā§āϰ āĻšāĻžāϰ | â | â |
āĻŦā§āϝāĻžāϞā§āύā§āϏ āĻļāĻŋāĻ
āĻŽā§āĻ āϏāĻŽā§āĻĒāĻĻ
āĻŽā§āĻ āĻĻāĻžā§
(USD) | āĻŽāĻžāϰā§āĻ ā§¨ā§Ļ⧍ā§Ģinfo | Y/Y āĻĒāϰāĻŋāĻŦāϰā§āϤāύ |
---|---|---|
āĻā§āϝāĻžāĻļ āĻ āĻāĻŽ āϏāĻŽā§ā§āϰ āĻŦāĻŋāύāĻŋā§ā§āĻ | ⧧⧍.ā§ā§Ŧ āĻā§ | ā§Š.ā§ā§¯% |
āĻŽā§āĻ āϏāĻŽā§āĻĒāĻĻ | ā§Šā§Ŧ.ā§Ēā§§Â āĻā§ | ⧍.ā§ā§¨% |
āĻŽā§āĻ āĻĻāĻžā§ | ⧍ā§Ē.ā§ā§¯Â āĻā§ | -ā§Ŧ.ā§Ļā§% |
āĻŽā§āĻ āĻāĻā§āĻāĻāĻŋ | ā§§ā§§.ā§Ŧā§¨Â āĻā§ | â |
āĻāĻāĻāϏā§āĻā§āϝāĻžāύā§āĻĄāĻŋāĻ āĻļā§ā§āĻžāϰ | ā§.ā§¨ā§ŠÂ āĻā§ | â |
āĻĒā§āϰāĻžāĻāϏ āĻā§ āĻŦā§āĻ āϰā§āĻļāĻŋāĻ | ā§§.ā§Ēā§Š | â |
āϏāĻŽā§āĻĒāĻĻ āĻĨā§āĻā§ āĻā§ | -⧝.ā§Ēā§Ž% | â |
āĻŽā§āϞāϧāύ āĻĨā§āĻā§ āĻā§ | -ā§§ā§Ŧ.ā§Ē⧍% | â |
āĻā§āϝāĻžāĻļ āĻĢā§āϞā§
āύāĻāĻĻā§ āĻŽā§āĻ āĻĒāϰāĻŋāĻŦāϰā§āϤāύ
(USD) | āĻŽāĻžāϰā§āĻ ā§¨ā§Ļ⧍ā§Ģinfo | Y/Y āĻĒāϰāĻŋāĻŦāϰā§āϤāύ |
---|---|---|
āύā§āĻ āĻāύāĻāĻžāĻŽ | -ā§§.ā§Žā§§Â āĻā§ | -ā§Ē⧍⧧.⧍ā§Ģ% |
āĻ
āĻĒāĻžāϰā§āĻļāύ āĻĨā§āĻā§ āĻĒāĻžāĻā§āĻž āĻā§āϝāĻžāĻļ | -ā§§.ā§ā§¨Â āĻā§ | ⧍ā§Ŧ.ā§Ēā§Ļ% |
āĻŦāĻŋāύāĻŋā§ā§āĻ āĻĨā§āĻā§ āĻĒā§āϰāĻžāĻĒā§āϤ āĻā§āϝāĻžāĻļ | ā§Ē⧍.ā§¨ā§ŠÂ āϞāĻž | ā§Šā§Ļā§Ģ.⧝ā§Ļ% |
āĻĢāĻžāĻāύā§āϝāĻžāύā§āϏāĻŋāĻ āĻĨā§āĻā§ āĻĒā§āϰāĻžāĻĒā§āϤ āĻā§āϝāĻžāĻļ | -ā§Ēā§Ļ.⧝ā§Ļ āϞāĻž | -ā§§ā§Šā§Ē.ā§Šā§Ž% |
āύāĻāĻĻā§ āĻŽā§āĻ āĻĒāϰāĻŋāĻŦāϰā§āϤāύ | -ā§§.ā§Ģā§Ŧ āĻā§ | -ā§§ā§Š.ā§Ŧā§% |
āĻĢā§āϰāĻŋ āĻā§āϝāĻžāĻļ āĻĢā§āϞ⧠| -ā§ā§Ļ.ā§¯ā§ŽÂ āϞāĻž | ā§Žā§Š.ā§Ŧā§Ļ% |
āϏāĻŽā§āĻĒāϰā§āĻā§
Cellectis is a French biopharmaceutical company. It develops genome-edited chimeric antigen receptor T-cell technologies for cancer immunotherapy. It has offices in Paris, New York City, and Raleigh, North Carolina. Wikipedia
āϏāĻŋāĻāĻ
āϏā§āĻĨāĻžāĻĒāĻŋāϤ āĻšā§ā§āĻā§
⧧⧝⧝⧝
āĻā§ā§āĻŦāϏāĻžāĻāĻ
āĻāϰā§āĻŽāĻāĻžāϰā§
⧍⧧⧝